Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 42 clinical trials
Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed Classical Hodgkin Lymphoma

enhances the immune system to better fight Hodgkin lymphoma cells. Giving brentuximab vedotin and nivolumab may be able to defer stem cell transplant treatment and spare the considerable cost and toxicity

  • 0 views
  • 25 Mar, 2022
  • 1 location
Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients (FIL_RENOIR12)

A randomized phase III multicenter trial assessing efficacy and toxicity of a combination of Rituximab and Lenalidomide (R2) vs Rituximab alone as maintenance after chemoimmunotherapy with Rituximab-chemotherapy (R-CHT) for relapsed/refractory FL patients not eligible for autologous transplantation (ASCT)

platelet count
bendamustine
rituximab
lenalidomide
neutrophil count
  • 55 views
  • 23 Mar, 2022
  • 28 locations
Interest of Individual Biomarkers From the Identification of Tumor Genotype by High-throughput Molecular Techniques

with a reduction in the amount of tumor DNA (ctDNA) in the blood, i.e. the genetic program of lymphoma cells that circulates freely in the blood. This evaluation of ctDNA has been made possible by the

follicular lymphoma
cancer
lymphoma
large b-cell lymphoma
lymphoma cells
  • 0 views
  • 01 Jan, 2022
  • 1 location
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

nelarabine to T-ALL and T-LLy patients with leukemia/lymphoma cells in cerebrospinal fluid at diagnosis or MRD ≥0.01% at the end of induction. To determine in a randomized study design whether the

bortezomib
lymphoma
flow cytometry
residual tumor
tyrosine
  • 278 views
  • 11 May, 2022
  • 7 locations
Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System (FIORELLA)

Primary central nervous system lymphomas are rare aggressive malignancies, usually treated in two steps: an induction phase (where a combination of chemotherapy is given) followed by a consolidation phase (where patients usually receive one of the following: whole-brain irradiation, chemotherapy supported by autologous stem-cell transplantation, other type of chemotherapy, or …

nervous
lenalidomide
maintenance treatment
rituximab
cancer
  • 0 views
  • 13 May, 2022
  • 35 locations
Single-Cell Map of Immune and Lymphoma Cells in B-cell Non-Hodgkin's Lymphoma (SIMILY)

This trial is a translational, prospective, open-label, monocentric research. The study will be conducted in a population of 60 patients with diffuse large B-cell lymphoma (DLBCL) for whom first-line treatment with R-CHOP is planned as part of their standard of care. SIMILY program aims at identifying biomarkers and/or molecular signatures …

  • 0 views
  • 21 Apr, 2022
  • 1 location
Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides

fungoides. Mogamulizumab (a humanized antibody) binds to CCR4, a protein often found in high amounts on T-cell lymphoma cells. Binding to these cells may slow their growth, as well as mark them for attack

lymphoma
skin biopsy
mycosis
cutaneous lymphoma
t-cell lymphoma
  • 0 views
  • 29 May, 2021
  • 1 location
Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma

drug. It works by using the antibody portion to enter into the lymphoma cells, and then releasing the drug portion to kill the lymphoma cells.

  • 0 views
  • 01 Oct, 2021
  • 3 locations
Lenalidomide Umbralisib and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

against cancer cells. Ublituximab is an antibody that attaches to the lymphoma cells and triggers immune reactions that may result in the death of the targeted lymphoma cells.

  • 0 views
  • 07 Dec, 2021
  • 1 location
Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma

pathways needed for cell growth. Immunotherapy with axicabtagene ciloleucel is engineered to target a specific surface antigen on lymphoma cells. Acalabrutinib may enhance the efficacy of axicabtagene

diffuse large b-cell lymphoma
oxygen saturation
flow cytometry
large b-cell lymphoma
measurable disease
  • 0 views
  • 25 Apr, 2022
  • 1 location